Eli Lilly welcomes you to a focused clinical webinar exploring the evolving paradigm of type 2 diabetes management beyond HbA1c reduction toward holistic metabolic improvement. In this session, the speaker will discuss how traditional glucose-centric targets may not fully capture the complex cardiometabolic nature of diabetes, highlighting the importance of addressing multiple metabolic parameters . The discussion will examine the limitations of relying solely on HbA1c and the growing emphasis on comprehensive metabolic control for improved long-term outcomes.
The webinar will also review emerging clinical evidence supporting incretin-based therapies and their effects across multiple cardiometabolic risk factors beyond glycemic control . Through an evidence-based overview, the session will highlight how these therapies contribute to broader metabolic benefits, reinforcing a shift…
